GoodRx (NASDAQ:GDRX) Stock Price Up 8.2% – Still a Buy?

GoodRx Holdings, Inc. (NASDAQ:GDRX) rose 8.2% during mid-day trading on Friday . The company traded as high as $4.64 and last traded at $4.64. Approximately 979,573 shares traded hands during trading, a decline of 32% from the average daily volume of 1,444,092 shares. The stock had previously closed at $4.29.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Barclays lowered their price objective on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 target price on shares of GoodRx in a research note on Friday, August 16th. Raymond James raised shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective for the company in a report on Friday, August 9th. UBS Group lowered their target price on GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research report on Friday, August 9th. Finally, Citigroup lowered their price target on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, GoodRx presently has an average rating of “Moderate Buy” and a consensus target price of $8.86.

GoodRx Stock Performance

The stock has a market cap of $1.87 billion, a PE ratio of -153.33, a PEG ratio of 3.09 and a beta of 1.39. The firm has a 50 day moving average of $6.28 and a two-hundred day moving average of $7.34. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48.

Insider Buying and Selling

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.17% of the stock is currently owned by company insiders.

Institutional Trading of GoodRx

A number of institutional investors have recently made changes to their positions in the stock. Barclays PLC lifted its holdings in shares of GoodRx by 1,316.1% during the 3rd quarter. Barclays PLC now owns 140,113 shares of the company’s stock valued at $973,000 after buying an additional 130,219 shares during the last quarter. Fortem Financial Group LLC bought a new position in shares of GoodRx in the third quarter worth about $772,000. Geode Capital Management LLC lifted its position in shares of GoodRx by 6.3% during the 3rd quarter. Geode Capital Management LLC now owns 982,729 shares of the company’s stock worth $6,823,000 after purchasing an additional 58,610 shares during the last quarter. Pier Capital LLC acquired a new stake in GoodRx in the 3rd quarter valued at approximately $3,259,000. Finally, EP Wealth Advisors LLC acquired a new position in shares of GoodRx during the third quarter worth approximately $73,000. 63.77% of the stock is owned by institutional investors and hedge funds.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.